LOTUS: Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata

Sponsor
The Cleveland Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01123603
Collaborator
(none)
860
1
49
17.5

Study Details

Study Description

Brief Summary

To the investigators knowledge there is no research data published to date regarding the lower urinary tract symptoms in women with leiomyomas. The primary aims of this study are:

  1. To determine prevalence of lower urinary tract symptoms in patients who present for care for symptomatic leiomyomata.

  2. To compare change in lower urinary tract symptoms within treatment groups measured by the UDI-6 total before and at six months after three common treatments for symptomatic uterine fibroids including: hysterectomy, myomectomy, or uterine artery embolization.

The study proposed here will hopefully answer the question if one particular therapy is appropriate to treat fibroids and relieve lower urinary tract symptoms.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    1. Uterine fibroids Uterine leiomyomas or fibroids are one of the most common conditions affecting women of reproductive age. They account for approximately a third of all hysterectomies performed. Symptoms often attributed to uterine leiomyomas include excessive menstrual bleeding, dysmenorrhea, pelvic pain, and so called "bulk symptoms," or symptoms related to pressure on adjacent organs such as ureteral obstruction, urinary frequency and urgency, rectal pressure, pelvic pressure and increasing abdominal girth. Current treatment for symptomatic uterine fibroids includes hysterectomy, myomectomy and uterine fibroid embolization.

    2. Lower urinary tract symptoms Although, urinary symptoms like frequency, urgency, incontinence, and voiding dysfunction are often attributed to fibroids, the relationship between fibroids and lower urinary tract symptoms (LUTS) has been poorly studied. The public health burden of fibroids has been studied before and after radical hysterectomy, supracervical hysterectomy, and total abdominal hysterectomy.(1-3) What is missing in the literature is a comparison of traditional and non-traditional surgical fibroid techniques in a prospective fashion. Moreover, there are no studies evaluating the relationship between anatomic factors like uterine size or fibroid number or location and the presence of LUTS.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    860 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Lower UTI Evaluation in Women With Uterine Leiomyomata
    Study Start Date :
    May 1, 2010
    Actual Primary Completion Date :
    Jun 1, 2014
    Actual Study Completion Date :
    Jun 1, 2014

    Outcome Measures

    Primary Outcome Measures

    1. To measure prevalence of lower urinary tract symptoms including urinary incontinence symptoms in patients who present for care for symptomatic leiomyomata. [Post treatment change]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients who are at least 18 years of age,

    • Vaginal bleeding secondary to anatomic uterine leiomyomas confirmed at the Cleveland Clinic Fibroid and Menstrual Disorders Center,

    • Patients complaining of mass effect symptoms due to fibroids, and

    • Patients undergoing either hysterectomy, myomectomy, or uterine artery embolization

    Exclusion Criteria:
    • Patients who are pregnant, or

    • Diagnosis of solitary or multiple intracavitary fibroids without subserosal or intramural leiomyomas present, or

    • Prior or interval anti-incontinence procedure, or

    • Patients with a urinary tract infection, or

    • Patients taking anti-cholinergic medications, or

    • Presence of an adnexal mass, or

    • Unable or unwilling to complete a follow up survey at six months following treatment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • The Cleveland Clinic

    Investigators

    • Study Director: Matthew Barber, MMD, The Cleveland Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Cleveland Clinic
    ClinicalTrials.gov Identifier:
    NCT01123603
    Other Study ID Numbers:
    • 09-923
    First Posted:
    May 14, 2010
    Last Update Posted:
    Jan 14, 2015
    Last Verified:
    Jan 1, 2015
    Keywords provided by The Cleveland Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 14, 2015